Li, Hongyu
Zhu, Biqing
Xu, Zhichao
Adams, Taylor
Kaminski, Naftali
Zhao, Hongyu
Article History
Received: 25 November 2020
Accepted: 15 September 2021
First Online: 26 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: NK served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, Veracyte, Augmanity and CSL Behring, over the last 3 years, reports Equity in Pliant and a grant from Veracyte, Boehringer Ingelheim, BMS and non-financial support from MiRagen and Astra Zeneca. NK has IP on novel biomarkers and therapeutics in IPF licensed to Biotech. The authors declare that they have no other competing interests.